The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.
SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patients for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life (HRQoL) will be evaluated for up to two years.
Study Type
OBSERVATIONAL
Enrollment
1,900
Physician's choice according to patient's needs. Routine care as per site standard.
Multiple sites, Gemany
Multiple Locations, Germany
RECRUITINGCourse of treatment (treatment reality)
Documentation of anamnestic data and therapy sequences
Time frame: 2 years per patient
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.